Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03743649
PHASE2/PHASE3

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.

Official title: Strategies for Persistent Agitated Delirium in Palliative Care

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2019-07-17

Completion Date

2026-12-31

Last Updated

2025-12-26

Healthy Volunteers

No

Interventions

DRUG

Haloperidol

Given IV

DRUG

Lorazepam

Given IV

OTHER

Placebo

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Locations (3)

M D Anderson Cancer Center

Houston, Texas, United States

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, United States

Hosptial de Cancer de Barretos

Barretos, São Paulo, Brazil